Epidemiology of Acute Polyradiculoneuritis at Fann Department of Neurology Dakar, Senegal
Clinical Neurology and Neuroscience
Volume 1, Issue 4, November 2017, Pages: 76-79
Received: Mar. 15, 2017; Accepted: Apr. 21, 2017; Published: Jun. 28, 2017
Views 1822      Downloads 92
Authors
Anna Modji Basse, Department of Neurology, Fann National Teaching Hospital, Dakar, Senegal
Soumaila Boubacar, Department of Neurology, Fann National Teaching Hospital, Dakar, Senegal
Adjaratou Dieynabou Sow, Department of Neurology, Fann National Teaching Hospital, Dakar, Senegal
Ngor Side Diagne, Department of Neurology, Fann National Teaching Hospital, Dakar, Senegal
Marième Soda Diop, Department of Neurology, Fann National Teaching Hospital, Dakar, Senegal
Ndiaga Matar Gaye, Department of Neurology, Fann National Teaching Hospital, Dakar, Senegal
Maouly Fall, Department of Neurology, Fann National Teaching Hospital, Dakar, Senegal
Ibrahima Mariam Diallo, Department of Neurology, Fann National Teaching Hospital, Dakar, Senegal
Ousmane Cisse, Department of Neurology, Fann National Teaching Hospital, Dakar, Senegal
Alassane Mamadou Diop, Department of Neurology, Fann National Teaching Hospital, Dakar, Senegal
Lala Bouna Seck, Department of Neurology, Fann National Teaching Hospital, Dakar, Senegal
Kamadore Touré, Department of Neurology, Fann National Teaching Hospital, Dakar, Senegal
Moustapha Ndiaye, Department of Neurology, Fann National Teaching Hospital, Dakar, Senegal
Amadou Gallo Diop, Department of Neurology, Fann National Teaching Hospital, Dakar, Senegal
Mouhamadou Mansour Ndiaye, Department of Neurology, Fann National Teaching Hospital, Dakar, Senegal
Article Tools
Follow on us
Abstract
The acute polyradiculoneuritis (APRN) Guillain Barre Syndrome (GBS) is the most typical case and best documented. In sub Saharan Africa, very few studies are conducted are peripheral neuropathies in general and the APR in particular. The goal of our was to determine the epidemiological profile of the patients hospitalized in our service and in the diagnosis of APRN was held. We had a retrospective study of descriptive type in Neurology department at the Fann National Teaching hospital in Dakar (Senegal). The software Epi Info6 has been used for the analysis and interpretation of data. A total 2694 patients hospitalized during the period of investigation, 39 patients (27 women and 12 men) were admitted for a GBS and which the diagnosis was retained as such depending on our criteria for inclusion. Thus, the hospital prevalence was 1.44%. The average age was 33.9 years with extremes of 11 and 74. The risk factors were dominated by the context of post-partum (63.6%) and type gastroenteritis infections (29.41%) and flu syndrome (23.5%). Albumino-cytological dissociation in the Cerebrospinal liquid (CSL) was objectified in 10 patients (45.4%) and the electroneuromyogram concluded in a demyelinating form in 48.4%, axonal form for 24% and a mixed form (27.7%). A corticosteroid therapy was administered at 53.4% of the patients. All patients had received a symptomatic and functional rehabilitation. Evolution in two months was marked by motor sequelae at 79.9%. Furthermore, 8 patients (20.5%) were transferred to unit and intensive care including mortality of (10.2%) had been recorded. Acute polyradiculoneuritis or Guillain Barre Syndrome have a professional impact. Primary prevention for reduction of morbidity and mortality attributable to this pathology.
Keywords
Guillain Barre Syndrome, Epidemiology, Dakar
To cite this article
Anna Modji Basse, Soumaila Boubacar, Adjaratou Dieynabou Sow, Ngor Side Diagne, Marième Soda Diop, Ndiaga Matar Gaye, Maouly Fall, Ibrahima Mariam Diallo, Ousmane Cisse, Alassane Mamadou Diop, Lala Bouna Seck, Kamadore Touré, Moustapha Ndiaye, Amadou Gallo Diop, Mouhamadou Mansour Ndiaye, Epidemiology of Acute Polyradiculoneuritis at Fann Department of Neurology Dakar, Senegal, Clinical Neurology and Neuroscience. Vol. 1, No. 4, 2017, pp. 76-79. doi: 10.11648/j.cnn.20170104.11
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Susanna Esposito, Maria Roberta Longo. Guillain–Barré syndrom. Autoimmunity Reviews 16 (2017) 96–101.
[2]
Ropper A. The Guillain–Barré symptom complex. N Engl J Med 1992; 17: 1130–6.
[3]
Schessl J, Luther B, Kirschener J, Mauff G, Korinthenberg R. Infections and vaccinations preceding childhood Guillain–Barré symptom complex: a prospective study. Eur J Pediatr 2006; 165: 605–12.
[4]
Landry O. Note sur la paralysie ascendante aiguë. Gazette Hebdomadaire Méd Chir 1859; 6: 472-4–486-8.
[5]
Pearce JM. Octave Landry’s ascending paralysis and the Landry-Guillain-Barre-Strohl syndrome. J Neurol Neurosurg Psychiatry 1997 May; 62 (5): 495-500.
[6]
Bogliun G, Beghi E. Incidence and clinical features of acute inflammatory polyradiculoneuropathy in Lombardy, Italy, 1996. Acta Neurol Scand 2004 Aug; 110 (2): 100-6.
[7]
Alshekhlee A, Hussain Z, Sultan B, Katirji B. Guillain-Barre syndrome: incidence and mortality rates in US hospitals. Neurology 2008 Apr 29; 70 (18): 1608-13.
[8]
Bogliun G, Beghi E. Incidence and clinical features of acute inflammatory polyradiculoneuropathy in Lombardy, Italy, 1996. Acta Neurol Scand 2004 Aug; 110 (2): 100-6.
[9]
Hughes RA, Cornblath DR. Guillain-Barre syndrome. Lancet 2005 Nov 5; 366 (9497): 1653-66.
[10]
van KR, van Doorn PA, Schmitz PI, Ang CW, van der Meche FG. Mild forms of Guillain- Barre syndrome in an epidemiologic survey in The Netherlands. Neurology 2000 Feb 8; 54 (3): 620-5.
[11]
Rees JH, Soudain SE, Gregson NA, Hughes RA. Campylobacter jejuni infection and Guillain-Barre syndrome. N Engl J Med 1995 Nov 23; 333 (21): 1374-9.
[12]
Ropper AH. The Guillain-Barre syndrome. N Engl J Med 1992 Apr 23; 326 (17): 1130-6.
[13]
van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 2008 Oct; 7 (10): 939-50.
[14]
Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol 1990; 27 Suppl: S21-S24.
[15]
Winer JB, Hughes RA, Osmond C. A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value. J Neurol Neurosurg Psychiatry 1988 May; 51 (5): 605-12.
[16]
Alain Créange. L’évolution de la conception de la polyradiculonévrite de Guillain-Barré. revue neurologique 1 7 3 S (2 0 1 7) S194–S199.
[17]
Albers JW, Donofrio PD, McGonagle TK. Sequential electrodiagnostic abnormalities in acute inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve, 1985 Jul; 8 (6): 528-39.
[18]
Pithadia AB, Kakadia N. Guillain–Barré syndrome. Pharmacol Rep 2010; 62: 220–32.
[19]
Vitaliti G, Tabatabaie O, Matin N, Ledda C, Pavone P, Lubrano R, Serra A, Di Mauro P, Cocuzza S, Falsaperla R. The usefulness of immunotherapy in pediatric neurodegenerativedisorders: a systematic review of literature data. Hum Vaccin Immunother 2015; 11: 2749–63.
[20]
CAMBIER J, BRUNET P. (1970). Le syndrome de Guillain et Barré. Paris: Eds JB Ballières et fils; p. 115.
[21]
PARRY GJ. (1993). Guillain-Barré syndrome. New-York; Thieme Medical Publishers, p. 200.
[22]
ROCA B, MENTERO A, SIMON E. (1997). Pain and opioid analgesicsin Guillain-Barré syndrome. Neurology, 48: 328-331.
[23]
R. Kabore, L. Magy, S. Boukhris, T. Mabrouk, M. Lacoste, J.-M. Vallat. Interêt de la corticothérapie dans le traitement de la douleur à la phase aiguë du syndrome de Guillain-Barré. Rev Neurol (Paris) 2004; 160: 8-9, 821-823.
[24]
SÀNCHEZ-GUERRA M, INFANTE J, PASCUAL J, BERCIANO J. (2002). Severe backache in Guillain-Barré syndrome. Muscle Nerve, 25: 468.
[25]
Liu J, Wang LN, McNicol ED. Pharmacological treatment for pain in Guillain–Barré syndrome. Cochrane Database Syst Rev 2015; 4, CD009950.
[26]
Ruts L, Drenthen J, Jongen JL, Hop WC, Visser GH, Jacobs BC, van Doorn PA, Dutch GBS Study Group. Pain in Guillain–Barré syndrome: a long-term follow-up study. Neurology 2010; 75: 1439–47.
[27]
Willison HJ, Jacobs BC, van Doorn PA. Guillain–Barré syndrome. Lancet 2016; 388: 717–27.
[28]
M. A. Gargouri, I. Bouchhima, E. Turki, M. Dammak, M. Imed Miladi, C. Mhiri. Aspects épidémiologiques, cliniques et évolutifs du syndrome de Guillain Barré dans la région de Sfax. revue neurologique 170 s (2014) a 33 – a 46 A37.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186